Tratamiento de la enfermedad de Alzheimer
Barra lateral del artículo
Contenido principal del artículo
Resumen
.
Downloads
Detalles del artículo
Sección
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Cómo citar
Referencias
Jorm AF, Jolley D. The incidence ofdementia: a meta-analysis. Neurology 1998;51(3):728-33. DOI: https://doi.org/10.1212/WNL.51.3.728
Mann DM, Marcyniuk B, Yates PO, et al.The progression of the pathological changes ofAlzheimer’s disease in frontal and temporalneocortex examined both at biopsy and atautopsy. Neuropathol Appl Neurobiol 1988;14(3):177-95. DOI: https://doi.org/10.1111/j.1365-2990.1988.tb00880.x
Joachim CL, Morris JH, Selkoe DJ. Diffusesenile plaques occur commonly in thecerebellum in Alzheimer’s disease. Am J Pathol1989; 135(2):309-19.
Braak H, Braak E. Neuropathologicalstageing of Alzheimer-related changes. ActaNeuropathol (Berl) 1991; 82(4):239-59. DOI: https://doi.org/10.1007/BF00308809
Delacourte A, David JP, Sergeant N, et al.The biochemical pathway of neurofibrillarydegeneration in aging and Alzheimer’s disease.Neurology 1999; 52(6):1158-65. DOI: https://doi.org/10.1212/WNL.52.6.1158
Hyman BT, Van Hoesen GW, Damasio AR,et al. Alzheimer’s disease: cell-specificpathology isolates the hippocampal formation.Science 1984; 225(4667):1168-70. DOI: https://doi.org/10.1126/science.6474172
Baskin DS, Browning JL, Pirozzolo FJ, etal. Brain choline acetyltransferase and mentalfunction in Alzheimer disease. Arch Neurol1999; 56(9):1121-3. DOI: https://doi.org/10.1001/archneur.56.9.1121
Schroder H, Zilles K, Luiten PG, et al.Human cortical neurons contain both nicotinicand muscarinic acetylcholine receptors: animmunocytochemical double-labeling study.Synapse 1989; 4(4):319-26. DOI: https://doi.org/10.1002/syn.890040408
Flynn DD, Ferrari-DiLeo G, Levey AI, et al.Differential alterations in muscarinic receptorsubtypes in Alzheimer’s disease: implicationsfor cholinergic-based therapies. Life Sci 1995;56(11-12):869-76. DOI: https://doi.org/10.1016/0024-3205(95)00022-X
Xu H, Sweeney D, Greengard P, et al.Metabolism of Alzheimer beta-amyloidprecursor protein: regulation by protein kinaseA in intact cells and in a cell-free system. ProcNatl Acad Sci U S A 1996; 93(9):4081-4. DOI: https://doi.org/10.1073/pnas.93.9.4081
Klunk WE, Debnath ML, Koros AM, et al.Chrysamine-G, a lipophilic analogue of Congored, inhibits A beta-induced toxicity in PC12cells. Life Sci 1998; 63(20):1807-14. DOI: https://doi.org/10.1016/S0024-3205(98)00454-8
Lee VM. Regulation of tau phosphorylationin Alzheimer’s disease. Ann N Y Acad Sci 1996;777:107-13. DOI: https://doi.org/10.1111/j.1749-6632.1996.tb34408.x
Morgan D. Immunotherapy for Alzheimer’sdisease. J Alzheimers Dis 2006; 9(3 Suppl):425-32.
Pappolla MA, Bryant-Thomas TK, HerbertD, et al. Mild hypercholesterolemia is an earlyrisk factor for the development of Alzheimeramyloid pathology. Neurology 2003; 61(2):199-205. DOI: https://doi.org/10.1212/01.WNL.0000070182.02537.84
Rea TD, Breitner JC, Psaty BM, et al. Statinuse and the risk of incident dementia: theCardiovascular Health Study. Arch Neurol2005; 62(7):1047-51. DOI: https://doi.org/10.1001/archneur.62.7.1047
Sidera C, Parsons R, Austen B. Theregulation of beta-secretase by cholesterol andstatins in Alzheimer’s disease. J Neurol Sci2005; 229-230:269-73. DOI: https://doi.org/10.1016/j.jns.2004.11.044
McGeer PL, Schulzer M, McGeer EG.Arthritis and anti-inflammatory agents aspossible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies.Neurology 1996; 47(2):425-32 DOI: https://doi.org/10.1212/WNL.47.2.425
Mrak RE, Sheng JG, Griffin WS. Glialcytokines in Alzheimer’s disease: review andpathogenic implications. Hum Pathol 1995;26(8):816-23. DOI: https://doi.org/10.1016/0046-8177(95)90001-2
Aisen PS, Davis KL. Inflammatorymechanisms in Alzheimer’s disease:implications for therapy. Am J Psychiatry 1994;151(8):1105-13. DOI: https://doi.org/10.1176/ajp.151.8.1105
Kuller LH, Tracy RP, Shaten J, et al. Relationof C-reactive protein and coronary heart diseasein the MRFIT nested case-control study.Multiple Risk Factor Intervention Trial. Am JEpidemiol 1996; 144(6):537-47. DOI: https://doi.org/10.1093/oxfordjournals.aje.a008963
Rogers J, Kirby LC, Hempelman SR, et al.Clinical trial of indomethacin in Alzheimer’sdisease. Neurology 1993; 43(8):1609-11. DOI: https://doi.org/10.1212/WNL.43.8.1609
Urani A, Privat A, Maurice T. Themodulation by neurosteroids of thescopolamine-induced learning impairment inmice involves an interaction with sigma1(sigma1) receptors. Brain Res 1998; 799(1):64-77. DOI: https://doi.org/10.1016/S0006-8993(98)00469-7
Shumaker SA, Legault C, Kuller L, et al.Conjugated equine estrogens and incidence ofprobable dementia and mild cognitiveimpairment in postmenopausal women:Women’s Health Initiative Memory Study.JAMA 2004; 291(24):2947-58. DOI: https://doi.org/10.1001/jama.291.24.2947
Birks J, Harvey RJ. Donepezil for dementiadue to Alzheimer’s disease. Cochrane DatabaseSyst Rev 2006; (1):CD001190. DOI: https://doi.org/10.1002/14651858.CD001190.pub2
Birks J. Cholinesterase inhibitors forAlzheimer’s disease. Cochrane Database SystRev 2006 Jan 25; (1):CD005593. DOI: https://doi.org/10.1002/14651858.CD005593
Duvoisin RC, Katz R. Reversal of centralanticholinergic syndrome in man byphysostigmine. JAMA 1968; 206(9):1963-5. DOI: https://doi.org/10.1001/jama.1968.03150090039008
Summers WK, Majovski LV, Marsh GM, etal. Oral tetrahydroaminoacridine in long-termtreatment of senile dementia, Alzheimer type.N Engl J Med 1986; 315(20):1241-5. DOI: https://doi.org/10.1056/NEJM198611133152001
Qizilbash N, Birks J, Lopez Arrieta J, et al.Tacrine for Alzheimer’s disease. CochraneDatabase Syst Rev 2000; (3):CD000202.
Cummings JL. Cholinesterase inhibitors: Anew class of psychotropic compounds. Am JPsychiatry 2000; 157(1):4-15. DOI: https://doi.org/10.1176/ajp.157.1.4
Golimstok A y col. Predictores de respuestaal tratamiento con tacrina en enfermedad deAlzheimer [abstract]. Rev Neurol Argent 1996.
Grupo de trabajo de Neurología delComportamiento y Neurociencias Cognitivas.Guía de práctica clínica en la Enfermedad deAlzheimer. Rev Neurol Argent 2006; 31(2):140-4.
Davidson M, Stern RG, Bierer LM, et al.Cholinergic strategies in the treatment ofAlzheimer’s disease. Acta Psychiatr ScandSuppl 1991; 366:47-51. DOI: https://doi.org/10.1111/j.1600-0447.1991.tb03109.x
Fioravanti M, Yanagi M. Cytidinediphos-phocholine (CDP-choline) for cognitive andbehavioural disturbances associated withchronic cerebral disorders in the elderly.Cochrane Database Syst Rev 2005; (2):CD000269. DOI: https://doi.org/10.1002/14651858.CD000269.pub2
Sano M, Ernesto C, Thomas RG, et al. Acontrolled trial of selegiline, alpha-tocopherol,or both as treatment for Alzheimer’s disease.The Alzheimer’s Disease Cooperative Study. NEngl J Med 1997; 336(17):1216-22 DOI: https://doi.org/10.1056/NEJM199704243361704
Masaki KH, Losonczy KG, Izmirlian G, etal. Association of vitamin E and C supplementuse with cognitive function and dementia inelderly men. Neurology 2000; 54(6):1265-72. DOI: https://doi.org/10.1212/WNL.54.6.1265
Mohr E, Schlegel J, Fabbrini G, et al.Clonidine treatment of Alzheimer’s disease.Arch Neurol 1989; 46(4):376-8. DOI: https://doi.org/10.1001/archneur.1989.00520400030015
Winblad B, Poritis N. Memantine in severedementia: results of the 9M-Best Study (Benefitand efficacy in severely demented patientsduring treatment with memantine). Int J GeriatrPsychiatry 1999; 14(2):135-46. DOI: https://doi.org/10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0
Tariot PN, Farlow MR, Grossberg GT, et al.Memantine treatment in patients with moderateto severe Alzheimer disease already receivingdonepezil: a randomized controlled trial. JAMA2004; 291(3):317-24. DOI: https://doi.org/10.1001/jama.291.3.317
Cummings JL, Schneider E, Tariot PN, etal. Behavioral effects of memantine inAlzheimer disease patients receiving donepeziltreatment. Neurology 2006; 67(1):57-63. DOI: https://doi.org/10.1212/01.wnl.0000223333.42368.f1
Croisile B, Trillet M, Fondarai J, et al. Long-term and high-dose piracetam treatment ofAlzheimer’s disease. Neurology 1993;43(2):301-5. DOI: https://doi.org/10.1212/WNL.43.2.301
Oken BS, Storzbach DM, Kaye JA. Theefficacy of Ginkgo biloba on cognitive functionin Alzheimer disease. Arch Neurol 1998;55(11):1409-15. DOI: https://doi.org/10.1001/archneur.55.11.1409
Taylor JE. Liaisons des neuromediateurs aleurs recepteurs dans le cerveau de rats. Effet del’administration chronique de l’extrait de Ginkgobiloba. Presse Med 1986; 15(31):1491-3.
Mangone CA. Enfermedad de Alzheimer.En: Micheli F, Nogués MA, Asconapé JJ, et al.Tratado de neurología clínica. Buenos Aires:Panamericana, 2002.
Crapper McLachlan DR, Dalton AJ, KruckTP, et al. Intramuscular desferrioxamine inpatients with Alzheimer’s disease. Lancet 1991;337(8753):1304-8. Errata en: Lancet 1991;337(8757):1618. DOI: https://doi.org/10.1016/0140-6736(91)92978-B